GSK’s $10.6B Nuvalent Deal & RSV Vaccine Boosts Oncology & Respiratory Growth
GSK’s $10.6B Nuvalent acquisition and adult RSV vaccine launch boost oncology and respiratory pipelines, diversifying revenue and mitigating patent cliffs.
4 minutes to read